Full-Time

Patient Access Liaison

Tepezza, Rare Disease

Confirmed live in the last 24 hours

Deadline 7/10/25
Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$169k - $198.6k/yr

+ Bonus + Sales-based Incentive Plan

Mid, Senior

St. Louis, MO, USA

Must live in territory, Missouri or Iowa.

Category
Customer Success
Sales & Account Management
Requirements
  • Doctorate degree and 2 years of patient services, and/or access and reimbursement, experience
  • Master's degree and 4 years of patient services, and/or access and reimbursement, experience
  • Bachelor's degree and 6 years of patient services, and/or access and reimbursement, experience
Responsibilities
  • Provide logistical, non-medical educational assistance to patients and caregivers as well as office and site of care staff, including physicians, nurses, office managers and executives
  • Secure written or electronic patient consent to Amgen By Your Side for patients in the assigned geography
  • Develop relationships with patients and caregivers by engaging via phone, text, email, virtual or in person connections
  • Assess individual needs of the patient and develop an appropriate education and resource plan of action, considering the patient’s family and team of healthcare providers to empower the patient to become their own advocate
  • Educate the patient on TEPEZZA coverage based on their benefits and the steps needed to gain prior authorization to ensure understanding of the process for medication access
  • Provide information on co-pay assistance programs, national foundations, and free drug programs by sharing information to patients as appropriate and needed
  • Provide proactive education to prescribers and sites of care upon patient enrollment on coverage for Amgen rare disease therapies, common prior authorization requirements, and coding and billings requirements
  • Investigate access challenges pre and post-infusion, to include support for denied claims and claim reviews
  • Partner with Safety and PV and report AE’s and product complaints through medical information
  • Adhere to professional standards compliance guidance, policies and procedures, federal, state, and local requirements
Desired Qualifications
  • Scientific background and ability to learn product and disease information
  • Nursing or other clinical background a plus
  • Access and reimbursement for buy and bill products
  • Orphan or Rare disease experience
  • Familiarity with HIPAA guidelines and FDA requirements
  • Familiarity with and Adherence to internal and OIG Compliance guidelines a must
  • Ability to handle difficult patient cases and resolve hurdles
  • Ability to work in a team environment and manage communication with case managers, Sales reps and Site of Care leads
  • Ability to respond immediately when necessary (within 24 hours) to prevent lapses in treatment
  • Strong analytical skills and strategic mindset
  • Proficient in Microsoft Office
  • Professional, proactive demeanor
  • Strong interpersonal skills
  • Excellent written and verbal communication skills
  • Ability and willingness to conduct field travel, as well as to travel to company meetings, client sites, etc. including some overnight and weekend travel

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's approach involves a strong commitment to research and development, allowing them to create new treatments and maintain a pipeline of potential therapies. Unlike many competitors, Amgen emphasizes biologic therapies and reinvests a large portion of its earnings back into R&D. The goal of Amgen is to improve patient care by providing effective treatments for serious health conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.